Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 15.33 USD 0.72% Market Closed
Market Cap: 824.9m USD
Have any thoughts about
Prothena Corporation PLC?
Write Note

Prothena Corporation PLC
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prothena Corporation PLC
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Prothena Corporation PLC
NASDAQ:PRTA
Selling, General & Administrative
-$67.3m
CAGR 3-Years
-15%
CAGR 5-Years
-14%
CAGR 10-Years
-13%
Alkermes Plc
NASDAQ:ALKS
Selling, General & Administrative
-$638.8m
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
-13%
Amarin Corporation PLC
NASDAQ:AMRN
Selling, General & Administrative
-$159.3m
CAGR 3-Years
28%
CAGR 5-Years
12%
CAGR 10-Years
-7%
No Stocks Found

Prothena Corporation PLC
Glance View

Market Cap
824.9m USD
Industry
Biotechnology

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

PRTA Intrinsic Value
36.55 USD
Undervaluation 58%
Intrinsic Value
Price

See Also

What is Prothena Corporation PLC's Selling, General & Administrative?
Selling, General & Administrative
-67.3m USD

Based on the financial report for Sep 30, 2024, Prothena Corporation PLC's Selling, General & Administrative amounts to -67.3m USD.

What is Prothena Corporation PLC's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-13%

Over the last year, the Selling, General & Administrative growth was -16%. The average annual Selling, General & Administrative growth rates for Prothena Corporation PLC have been -15% over the past three years , -14% over the past five years , and -13% over the past ten years .

Back to Top